Skip to main content
SpringerLink
Log in

Prostate Cancer Emergencies

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2964 Accesses

Abstract

Urological emergencies of prostate cancer are increasingly becoming more common and may present to emergency departments, general physicians, and urologists. Importantly, they may result in pain and discomfort (urinary retention and skeletal fractures), loss of function (neurological complication or priapism), or in rare cases death (bone fractures, infected obstructed kidneys, and sepsis). Hence, it is mandatory to have a full understanding of the clinical presentation of these emergencies, and in addition, appreciation of rapid diagnosis and expeditious treatment is mandatory. This chapter reviews the presentation, diagnosis, and clinical treatment of acute emergencies related to prostate cancer and the complications of treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Full NICE Guidelines. Metastatic cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. Cardiff: National Collaborating Centre for Cancer; Nov 2008.

    Google Scholar 

  2. Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:20–7.

    Article  PubMed  CAS  Google Scholar 

  3. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.

    Article  PubMed  CAS  Google Scholar 

  4. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48:88–95.

    Article  PubMed  CAS  Google Scholar 

  5. Cervantes A, Chirivella I. Oncological emergencies. Ann Oncol. 2004;15 Suppl 4:iv299–306.

    PubMed  Google Scholar 

  6. Stewart AF. Hypercalceamia associated with cancer. N Engl J Med. 2005;352:373–9.

    Article  PubMed  CAS  Google Scholar 

  7. Walji N, Chan AK, Peake DR. Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J. 2008;84:418–27.

    Article  PubMed  CAS  Google Scholar 

  8. Thirlwell C, Brock C. Emergencies in oncology. Clin Med. 2003;3:306–10.

    PubMed  Google Scholar 

  9. Pavalakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474.

    Google Scholar 

  10. Saunders Y, Ross JR, Broadley KE, Edmunds PM, Patel S. Systematic review of bisphosphonates for hypercalceamia of malignancy. Palliat Med. 2004;18:418–31.

    Article  PubMed  CAS  Google Scholar 

  11. Samphao S, Eremin JM, Eremin O. Oncological emergencies: clinical importance and principles of management. Eur J Cancer. 2010;19(6):707–13.

    Article  CAS  Google Scholar 

  12. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 2007;1117:209–57.

    Article  PubMed  CAS  Google Scholar 

  13. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III, double blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–7.

    Article  PubMed  CAS  Google Scholar 

  14. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.

    Article  PubMed  CAS  Google Scholar 

  15. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid treatment of post menopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.

    Article  PubMed  CAS  Google Scholar 

  16. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328–31.

    Article  PubMed  Google Scholar 

  17. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek et al. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). In: ASCO annual meeting, Orlando, 2009.

    Google Scholar 

  18. Bucholtz JD. Metastatic epidural spinal cord compression. Semin Oncol Nurs. 1999;15:150–9.

    Article  PubMed  CAS  Google Scholar 

  19. Sorensen PS, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer. 1994;30A:22–7.

    Article  PubMed  CAS  Google Scholar 

  20. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23:2028–37.

    Article  PubMed  Google Scholar 

  21. Klimo P, Thompson CJ, Kestle JR, Schmidt MH. A metaanalysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neurooncology. 2005;7(1):64–76.

    Google Scholar 

  22. Patchell RA, Tibbs PA, Regine WF, Payne R. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial. Lancet. 2005;366:643–8.

    Article  PubMed  Google Scholar 

  23. Russo P. Urologic emergencies in the cancer patient. Semin Oncol. 2000;27(3):284–98.

    PubMed  CAS  Google Scholar 

  24. Chiou RK, Chang WY, Horan JJ. Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol. 1990;143:957–9.

    PubMed  CAS  Google Scholar 

  25. Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol. 2007;178(1):178–83.

    Article  PubMed  Google Scholar 

  26. Lienert A, Ing A, Mark S. Prognostic factors in malignant obstruction. BJU. 2009;104(7):938–41.

    Article  CAS  Google Scholar 

  27. Paul AB, Love C, Chisholm GD. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br J Urol. 1994;74(5):642–5.

    Article  PubMed  CAS  Google Scholar 

  28. Harris MR, Speakman MJ. Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit? Prostate Cancer Prostatic Dis. 2006;9:42–4.

    Article  PubMed  CAS  Google Scholar 

  29. Donat SM, Russo P. Ureteral decompression in advanced nonurologic malignancies. Ann Surg Oncol. 1996;3:393–9.

    Article  PubMed  CAS  Google Scholar 

  30. Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl. 2005;87:21–4.

    Article  PubMed  CAS  Google Scholar 

  31. Rackson ME, Mitty HA, Lossef SV, et al. Biocompatible copolymer ureteric stent: maintenance of patency beyond 6 months. Am J Radiol. 1989;153:783–4.

    CAS  Google Scholar 

  32. Rollig C, Wockel A, Weibach L. Management of obstructive uropathy patients with advanced prostate cancer – a systematic review. Oncology. 2009;32(11):680–4. Epub 2009 Oct 16.

    Article  Google Scholar 

  33. Ku JH, Lee SW, Jeon HG, Kim HH, Oh SJ. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology. 2004;64:895–9.

    Article  PubMed  Google Scholar 

  34. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17–60.

    Article  PubMed  Google Scholar 

  35. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103:1103–13.

    Article  PubMed  Google Scholar 

  36. Middleman EL, Watanabe A, Kaizer H, et al. Antibiotic combinations for infections in neutropenic patients. Evaluation of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972;30: 573–9.

    Article  PubMed  CAS  Google Scholar 

  37. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for use of white blood cell growth factors: an evidence based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    Article  PubMed  CAS  Google Scholar 

  38. Fleischmann JD, Catalona WJ. Endrocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol. 1985;134:498–500.

    PubMed  CAS  Google Scholar 

  39. Ornstein DK, Rao SR, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol. 1997;157:880–4.

    Article  PubMed  CAS  Google Scholar 

  40. Chang C, Kuo JY, Chen KK, et al. Transurethral prostatic resection for acute urinary retention in patients with prostate cancer. J Chin Med Assoc. 2006;69:21–5.

    Article  PubMed  Google Scholar 

  41. Mazur AW, Thompson IM. Efficacy and morbidity of “channel” TURP. Urology. 1991;38:526–8.

    Article  PubMed  CAS  Google Scholar 

  42. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004;171:668–71.

    Article  PubMed  Google Scholar 

  43. Yang JX. Transurethral resection of the prostate for advanced hormone-refractory prostate cancer: a feasibility study. Zhonghua Nan Ke Xue. 2011;17(1):55–8.

    PubMed  CAS  Google Scholar 

  44. Wu WC, Schifftner TL, Henderson WG, et al. Preoperative hematocrit levels and post operative outcomes in older patients undergoing non cardiac surgery. JAMA. 2007;297:2481–8.

    Article  PubMed  CAS  Google Scholar 

  45. Caro JJ, Salas M, Ward A, et al. Aneamia as an independent prognostic factor for survival in patients with cancer. Cancer. 2001;91:2214–21.

    Article  PubMed  CAS  Google Scholar 

  46. Khafagy R, Shackley D, Samuel J, et al. Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med. 2007;10:705–11.

    Article  PubMed  Google Scholar 

  47. Strum SB, McDermed JE, Scholz MC, et al. Aneamia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933–41.

    Article  PubMed  CAS  Google Scholar 

  48. Harrison L, Shasha D, Shiaova L, et al. Prevalence of aneamia in cancer patients undergoing radiation therapy. Semin Oncol. 2001;28(2 Suppl 8):54–9.

    Article  PubMed  CAS  Google Scholar 

  49. Colloca G, Venturino A, Vitucci P, Gianni W. Management of aneamia in prostate cancer. Cancer Invest. 2010;28:280–8.

    Article  PubMed  Google Scholar 

  50. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am. 2006;33:167–79.

    Article  PubMed  Google Scholar 

  51. Ots PM, Perez AR, Carrizosa CL, et al. Once weekly dose of radiotherepoetin alfa in cancer patients with aneamia receiving radiotherapy. Clin Transl Oncol. 2005;7(11):486–92.

    Article  PubMed  Google Scholar 

  52. Egea M, Doria F, Martinez-Valis GPL, et al. Metastasis priapism. A report of 4 new cases and review of literature. Arch Esp Urol. 2000;53(5):447–52.

    Google Scholar 

  53. Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corpora smooth muscle dysfunction: a model for ischeamic priapism. J Urol. 1994;151:259–62.

    PubMed  CAS  Google Scholar 

  54. Keoghane SR, Sullivan ME, Miller MAW. The aetiology, pathogenesis and management of priapism. BJU Int. 2002;90(2):149–54.

    Article  PubMed  CAS  Google Scholar 

  55. Montague DK, Jamow J, Brodorick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4):1318–24.

    Google Scholar 

  56. Castro Beza I, Sanchez Ruiz J, et al. Drug related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol. 2008;10:591–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham, Wales, LL13 7TD, UK

    Bethan C. Hickerton MBChB, MRCS, Mohamed Ismat Abdulmajed MBChB. & Iqbal S. Shergill B.Sc. (Hons), MRCS (Eng), FRCS (Urol)

  2. Department of Urology, University College Hospital and The Barts Cancer Institute, London, UK

    Manit Arya MBChB, M.D., FRCS (Glasgow), FRCS (Urol)

Authors
  1. Bethan C. Hickerton MBChB, MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Ismat Abdulmajed MBChB.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manit Arya MBChB, M.D., FRCS (Glasgow), FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iqbal S. Shergill B.Sc. (Hons), MRCS (Eng), FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bethan C. Hickerton MBChB, MRCS .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Hickerton, B.C., Abdulmajed, M.I., Arya, M., Shergill, I.S. (2013). Prostate Cancer Emergencies. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_86

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_86

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation